Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7

PLoS Pathogens

Volumn 8, Issue 5, 2012, Pages

  Parrish, Nicholas F ^a,b   Wilen, Craig B ^a,b   Banks, Lauren B ^a,b   Iyer, Shilpa S ^a,b   Pfaff, Jennifer M ^a   Salazar Gonzalez, Jesus F ^c   Salazar, Maria G ^c   Decker, Julie M ^c   Parrish, Erica H ^a,b   Berg, Anna ^d   Hopper, Jennifer ^d   Hora, Bhavna ^d   Kumar, Amit ^d   Mahlokozera, Tatenda ^d   Yuan, Sally ^a   Coleman, Charl ^e   Vermeulen, Marion ^e   Ding, Haitao ^c   Ochsenbauer, Christina ^c   Tilton, John C ^f   Permar, Sallie R ^d   Kappes, John C ^c   Betts, Michael R ^a   Busch, Michael P ^g   Gao, Feng ^d   Montefiori, David ^d   Haynes, Barton F ^d   Shaw, George M ^a,b   Hahn, Beatrice H ^a,b   Doms, Robert W ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Alabama at Birmingham   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SOUTH AFRICAN NATIONAL BLOOD SERVICE   (South Africa)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA7 INTEGRIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; INTEGRIN ALPHA4BETA7; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; INTEGRIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MOLECULAR CLONING; NONHUMAN; VIRUS ENVELOPE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; CELL CULTURE; CHEMISTRY; CYTOLOGY; DISEASE TRANSMISSION; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MUCOSA; PATHOGENICITY; SERODIAGNOSIS; VIRAL TROPISM; VIROLOGY; VIRUS ENTRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLONING, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; INTEGRINS; MUCOUS MEMBRANE; NEUTRALIZATION TESTS; RECEPTORS, CCR5; VIRAL TROPISM; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84863696607     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002686     Document Type: Article

References (89)

1. Wolfs TF, Zwart G, Bakker M, Goudsmit J, (1992) HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 189: 103-110.
2. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, et al. (1992) Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255: 1134-1137.
3. McNearney T, Hornickova Z, Markham R, Birdwell A, Arens M, et al. (1992) Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A 89: 10247-10251.
4. Pang S, Shlesinger Y, Daar ES, Moudgil T, Ho DD, et al. (1992) Rapid generation of sequence variation during primary HIV-1 infection. AIDS 6: 453-460.
5. Cichutek K, Merget H, Norley S, Linde R, Kreuz W, et al. (1992) Development of a quasispecies of human immunodeficiency virus type 1 in vivo. Proc Natl Acad Sci U S A 89: 7365-7369.
6. Zhu T, Mo H, Wang N, Nam DS, Cao Y, et al. (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261: 1179-1181.
7. Delwart E, Magierowska M, Royz M, Foley B, Peddada L, et al. (2002) Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 16: 189-195.
8. Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattacharya T, et al. (2011) Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci U S A 108: E1156-1163.
9. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82: 3952-3970.
10. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
11. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5: e1000274.
12. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, et al. (2009) Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 83: 3556-3567.
13. Li H, Bar KJ, Wang S, Decker JM, Chen Y, et al. (2010) High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 6: e1000890.
14. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, et al. (2010) Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 84: 6241-6247.
15. Shaw GM, Hunter E, (2011) HIV Transmission. In: Bushman FD, Nabel GJ, Swanstrom R, editors. HIV: From Biology to Prevention and Treatment Cold Spring Harbor, New York Cold Spring Harbor Laboratory Press pp. 135-151.
16. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, et al. (2012) Presence of CXCR4-Using HIV-1 in Patients With Recently Diagnosed Infection: Correlates and Evidence for Transmission. J Infect Dis 205: 174-184.
17. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, et al. (2009) Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 83: 8208-8220.
18. Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, et al. (2010) Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J Virol 84: 4100-4104.
19. Asmal M, Hellmann I, Liu W, Keele BF, Perelson AS, et al. (2011) A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS One 6: e23673.
20. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, et al. (2011) Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 85: 8514-8527.
21. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
22. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790.
23. Etemad B, Fellows A, Kwambana B, Kamat A, Feng Y, et al. (2009) Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol 83: 9694-9708.
24. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206: 1253-1272.
25. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206: 1273-1289.
26. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, et al. (2012) Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. J Virol 86: 2715-2728.
27. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, et al. (2005) Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 79: 6528-6531.
28. Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, et al. (2005) Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 79: 6523-6527.
29. Sagar M, Wu X, Lee S, Overbaugh J, (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80: 9586-9598.
30. Sagar M, Laeyendecker O, Lee S, Gamiel J, Wawer MJ, et al. (2009) Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis 199: 580-589.
31. Curlin ME, Zioni R, Hawes SE, Liu Y, Deng W, et al. (2010) HIV-1 envelope subregion length variation during disease progression. PLoS Pathog 6: e1001228.
32. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, et al. (2011) Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 7: e1002209.
33. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, et al. (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9: 301-309.
34. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, et al. (2009) The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 106: 20877-20882.
35. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, et al. (2011) The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog 7: e1001301.
36. Cicala C, Arthos J, Fauci AS, (2011) HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med 9 (Suppl 1): S2.
37. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, et al. (2011) Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of their Replication Capacity in CD4 T-Lymphocytes and Monocyte-derived Macrophages. J Virol 86: 2715-28.
38. Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, et al. (2011) Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol 85: 10669-10681.
39. Kraus MH, Parrish NF, Shaw KS, Decker JM, Keele BF, et al. (2010) A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. Virology 397: 346-357.
40. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871-1879.
41. Kirchherr JL, Hamilton J, Lu X, Gnanakaran S, Muldoon M, et al. (2011) Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology 409: 163-174.
42. Fouda GG, Yates NL, Pollara J, Shen X, Overman GR, et al. (2011) HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol 85: 9555-9567.
43. Cohen MS, (2007) CHAVI 001: Acute HIV-1 Infection Prospective Cohort Study. 2.0 ed. https://chavi.org/wysiwyg/downloads/CHAVI_001_protocol_v2.pdf: Center for HIV/AIDS Vaccine Immunology (CHAVI).
44. Salazar-Gonzalez JF, Salazar MG, Learn GH, Fouda GG, Kang HH, et al. (2011) Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol 85: 2751-2763.
45. Collman R, Hassan NF, Walker R, Godfrey B, Cutilli J, et al. (1989) Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J Exp Med 170: 1149-1163.
46. Shioda T, Levy JA, Cheng-Mayer C, (1991) Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349: 167-169.
47. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, et al. (1996) A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158.
48. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673.
49. Pfaff JM, Wilen CB, Harrison JE, Demarest JF, Lee B, et al. (2010) HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol 84: 6505-6514.
50. Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, et al. (2009) A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol 83: 11016-11026.
51. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819-822.
52. Brighty DW, Rosenberg M, Chen IS, Ivey-Hoyle M, (1991) Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci U S A 88: 7802-7805.
53. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, et al. (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81: 2359-2371.
54. Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, et al. (2010) HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses 26: 13-24.
55. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, et al. (1990) Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A 87: 6058-6062.
56. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, et al. (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 185: 1681-1691.
57. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW, (1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 96: 5215-5220.
58. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
59. Sallusto F, Geginat J, Lanzavecchia A, (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763.
60. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
61. Farstad IN, Halstensen TS, Lien B, Kilshaw PJ, Lazarovits AI, et al. (1996) Distribution of beta 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue. Immunology 89: 227-237.
62. Farstad IN, Halstensen TS, Kvale D, Fausa O, Brandtzaeg P, (1997) Topographic distribution of homing receptors on B and T cells in human gut-associated lymphoid tissue: relation of L-selectin and integrin alpha 4 beta 7 to naive and memory phenotypes. Am J Pathol 150: 187-199.
63. McKinnon LR, Nyanga B, Chege D, Izulla P, Kimani M, et al. (2011) Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol 187: 6032-6042.
64. Pauls E, Ballana E, Moncunill G, Bofill M, Clotet B, et al. (2009) Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS 23: 266-268.
65. O'Doherty U, Swiggard WJ, Malim MH, (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74: 10074-10080.
66. Platt EJ, Kozak SL, Durnin JP, Hope TJ, Kabat D, (2010) Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J Virol 84: 3106-3110.
67. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: e23521.
68. Meissner EG, Duus KM, Gao F, Yu XF, Su L, (2004) Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology 328: 74-88.
69. Bednarczyk JL, Teague TK, Wygant JN, Davis LS, Lipsky PE, et al. (1992) Regulation of T cell proliferation by anti-CD49d and anti-CD29 monoclonal antibodies. J Leukocyte Biol 52: 456-462.
70. Bednarczyk JL, McIntyre BW, (1990) A monoclonal antibody to VLA-4 alpha-chain (CDw49d) induces homotypic lymphocyte aggregation. J Immunol 144: 777-784.
71. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
72. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR, (1997) The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 94: 1925-1930.
73. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM, (1998) Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 72: 2733-2737.
74. Hedskog C, Mild M, Albert J, (2012) Transmission of the X4 Phenotype of HIV-1: Is There Evidence Against the "Random Transmission" Hypothesis? J Infect Dis 205: 163-165.
75. Hladik F, Hope TJ, (2009) HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 6: 20-28.
76. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749-759.
77. Ansari AA, Reimann KA, Mayne AE, Takahashi Y, Stephenson ST, et al. (2011) Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 186: 1044-1059.
78. Chesebro B, Wehrly K, (1988) Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 62: 3779-3788.
79. Pohlmann S, Baribaud F, Lee B, Leslie GJ, Sanchez MD, et al. (2001) DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol 75: 4664-4672.
80. Pohlmann S, Soilleux EJ, Baribaud F, Leslie GJ, Morris LS, et al. (2001) DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A 98: 2670-2675.
81. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
82. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, et al. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307-321.
83. Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, et al. (2004) Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 78: 1718-1729.
84. Emmelkamp JM, Rockstroh JK, (2007) CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 12: 409-417.
85. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
86. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
87. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R, (2011) HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog 7: e1002286.
88. Soda Y, Shimizu N, Jinno A, Liu HY, Kanbe K, et al. (1999) Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 258: 313-321.
89. Lazarovits AI, Moscicki RA, Kurnick JT, Camerini D, Bhan AK, et al. (1984) Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol 133: 1857-1862.